6.57
+0(+0.00%)
Currency In USD
| Previous Close | 6.57 |
| Open | 6.5 |
| Day High | 6.93 |
| Day Low | 6.47 |
| 52-Week High | 14.6 |
| 52-Week Low | 3.79 |
| Volume | 640,261 |
| Average Volume | 978,217 |
| Market Cap | 350.34M |
| PE | -4.94 |
| EPS | -1.33 |
| Moving Average 50 Days | 5.73 |
| Moving Average 200 Days | 6.36 |
| Change | 0 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $938.57 as of July 31, 2025 at a share price of $6.57. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 2 years ago, it would be worth $2,154.1 as of July 31, 2025 at a share price of $6.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Yesterday at 12:05 PM GMT
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
GlobeNewswire Inc.
Jul 24, 2025 12:05 PM GMT
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
GlobeNewswire Inc.
Jul 09, 2025 12:05 PM GMT
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer